Literature DB >> 4787856

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

H Stähelin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4787856     DOI： 10.1016/s0014-2964(73)80021-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  32 in total

1.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Design, synthesis, and cytotoxicity of perbutyrylated glycosides of 4β-triazolopodophyllotoxin derivatives.

Authors:  Cheng-Ting Zi; Zhen-Hua Liu; Gen-Tao Li; Yan Li; Jun Zhou; Zhong-Tao Ding; Jiang-Miao Hu; Zi-Hua Jiang
Journal:  Molecules       Date:  2015-02-16       Impact factor: 4.411

Review 4.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.

Authors:  J D Loike
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.

Authors:  R T Dorr; D S Alberts
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

Authors:  F C Schell; H Y Yap; G N Hortobagyi; B Issell; L Esparza
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.

Authors:  T Colombo; M Broggini; L Torti; E Erba; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.